(Q43695468)

25 November 2017

title

Aclidinium bromide/formoterol fumarate fixed-dose combination for the treatment of chronic obstructive pulmonary disease (English)

1 reference

chronic obstructive pulmonary disease

25 November 2017

main subject

1 reference

2

1 reference

25 November 2017

Mario Cazzola

1

1 reference

25 November 2017

Maria Gabriella Matera

series ordinal

3

1 reference

25 November 2017

language of work or name

English

0 references

publication date

9 March 2013

1 reference

Expert Opinion on Pharmacotherapy

25 November 2017

published in

1 reference

25 November 2017

volume

14

1 reference

25 November 2017

issue

6

1 reference

25 November 2017

page(s)

775-781

1 reference

Comparison of three combined pharmacological approaches with tiotropium monotherapy in stable moderate to severe COPD: a systematic review.

25 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.776539

The scientific rationale for combining long-acting beta2-agonists and muscarinic antagonists in COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.776539

β(2) -adrenoceptor agonists: current and future direction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.776539

Pharmacology and therapeutics of bronchodilators

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.776539

Clinical and economic outcomes of multiple versus single long-acting inhalers in COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.776539

Incremental third-party costs associated with COPD exacerbations: a retrospective claims analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.776539

Change in asthma and COPD prescribing by Italian general practitioners between 2006 and 2008.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.776539

Cost effectiveness of pharmacological maintenance treatment for chronic obstructive pulmonary disease: a review of the evidence and methodological issues

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.776539

Comparison of resource use by COPD patients on inhaled therapies with long-acting bronchodilators: a database study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.776539

Combination of formoterol and tiotropium in the treatment of COPD: effects on lung function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.776539

Novel bronchodilators for the treatment of chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.776539

Aclidinium bromide, a new, long-acting, inhaled muscarinic antagonist: in vitro plasma inactivation and pharmacological activity of its main metabolites.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.776539

Safety and pharmacokinetics of multiple doses of aclidinium bromide, a novel long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease, in healthy participants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.776539

An update on bronchodilators in Phase I and II clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.776539

Inhaled beta2-adrenoceptor agonists: cardiovascular safety in patients with obstructive lung disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.776539

The cardiovascular risk of tiotropium: is it real?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.776539

Diagnosis and Management of Stable Chronic Obstructive Pulmonary Disease: A Clinical Practice Guideline Update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.776539

Night-time symptoms: a forgotten dimension of COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.776539

Optimum bronchodilator combinations in chronic obstructive pulmonary disease: what is the current evidence?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.776539

Beyond lung function in COPD management: effectiveness of LABA/LAMA combination therapy on patient-centred outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.776539

Outcomes for COPD pharmacological trials: from lung function to biomarkers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.776539

Symptom variability in patients with severe COPD: a pan-European cross-sectional study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.776539

Efficacy and safety of twice-daily aclidinium bromide in COPD patients: the ATTAIN study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.776539

10.1517/14656566.2013.776539

21 January 2018

Identifiers

DOI

1 reference

25 November 2017

1 reference